PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12673723-9	2003	The cytochrome P450 2D6 locus, known to be mutated at high frequencies in NF2 patients and to be specifically inhibited by quinidine, was screened for mutations by cycle sequencing.	Quinidine	123-132	cytochrome P450 2D6	Homo sapiens	4-23	
1611804-0	1992	Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.	Quinidine	73-82	cytochrome P450 2D6	Homo sapiens	106-124	
9103485-1	1997	Enzymatic conversion of hydrocodone to hydromorphone is catalyzed by cytochrome P450 2D6, which is inactive in about 7% of Caucasians [poor metabolizers (PMs)] and can be inhibited by quinidine pretreatment in the remainder [extensive metabolizers (EMs)].	Quinidine	184-193	cytochrome P450 2D6	Homo sapiens	69-88	
8138941-5	1994	Quinidine was a highly potent inhibitor of 2-OH-DMI formation (mean Ki = 0.053 microM), consistent with the presumed role of Cytochrome P450-2D6 in mediating this reaction.	Quinidine	0-9	cytochrome P450 2D6	Homo sapiens	125-144	
9758674-0	1998	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.	Quinidine	74-83	cytochrome P450 2D6	Homo sapiens	41-60	
1611804-7	1992	Based on the brain/plasma ratio for dextromethorphan in rats, it is estimated that brain dextromethorphan concentrations of 1.0 to 10 micrograms/gm may be attainable in humans by inhibition of cytochrome P4502D6 activity with quinidine.	Quinidine	226-235	cytochrome P450 2D6	Homo sapiens	193-211	
1611804-3	1992	The purpose of this research was to determine whether quinidine (a selective inhibitor of cytochrome P4502D6) could improve dextromethorphan systemic delivery in patients with amyotrophic lateral sclerosis (a neurodegenerative disease).	Quinidine	54-63	cytochrome P450 2D6	Homo sapiens	90-108	
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Quinidine	4-13	cytochrome P450 2D6	Homo sapiens	45-64	
26000221-6	2014	To block DM hepatic metabolism, thereby increasing DM bioavailability, Quinidine, a cytochrome P450 2D6 inhibitor, is coadministered at a dosage well below those for treating cardiac arrhythmia.	Quinidine	71-80	cytochrome P450 2D6	Homo sapiens	84-103